Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Stomach Neoplasms 1Squamous NSCLC 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Colonic Neoplasms 1CRC 1

Interventions

Carboplatin 71Etoposide 63Topotecan 42Cisplatin 38pembrolizumab 30atezolizumab 26durvalumab 22Paclitaxel 16Nivolumab 14PM 01183 13rovalpituzumab tesirine 11Pemetrexed 11amrubicin 9Ipilimumab 9Injections 9Irinotecan 8AMG 757 8trilaciclib 7etoposide phosphate 6EC regimen 6Drug Therapy 6Docetaxel 6Bevacizumab 6tremelimumab 5MLN 8237 5Gemcitabine 5130-nm albumin-bound paclitaxel 5olaparib 4chiauranib 4budigalimab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Small Cell Lung Carcinoma × HLX07 × Clear all
NCT05354700 2022-05-04

A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer

Shanghai Henlius Biotech

Phase 2 Unknown
20 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡